^
    over2years
    Efficacy of dacomitinib in patients with non-small cell lung cancer carrying complex EGFR mutations: a real-world study. (PubMed, J Thorac Dis)
    This study indicated a worse response and prognosis of patients with NSCLC harboring complex EGFR mutations than those harboring common EGFR mutations when treated with dacomitinib. Further studies and data are needed to confirm this conclusion.
    Journal • Real-world evidence
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 18 mutation • EGFR G724S • EGFR K754E
    |
    Vizimpro (dacomitinib)
    almost4years
    Efficacy of afatinib for pulmonary adenocarcinoma with leptomeningeal metastases harboring an epidermal growth factor receptor complex mutation (exon 19del+K754E): A case report. (PubMed, Medicine (Baltimore))
    This is the first case report of clinical improvement after afatinib treatment in a patient with lung adenocarcinoma and leptomeningeal metastasis harboring an EGFR complex mutation (exon19del+K754E), and thus provides a clinical reference for treatment with afatinib of cancers harboring EGFR compound mutations.
    Clinical • Journal
    |
    EGFR (Epidermal growth factor receptor) • CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    EGFR mutation • EGFR K754E
    |
    Tagrisso (osimertinib) • Gilotrif (afatinib) • gefitinib